Dr Reddys Laboratories  clarified on news report titled, "DRL under health Canada Scanner" in Asian Age.

The company said, "In keeping with current regulations of Health Canada, the company has voluntarily placed under quarantine all APIs and the formulations based on APIs produced at our API facility in Srikakulam district of Andhra Pradesh intended for use in Canada. Our products continue to meet intended quality standards, and we believe that, our APIs and Finished drug products manufactured using these APIs pose no risk to the health and safety of the Canadian people. The company is working with the agency for a satisfactory resolution of the matter. At this stage, it has no implication on any activity at the plant and hence, these are not expected to be material to the company's operations or consolidated results."

Shares of the company declined Rs 9.3, or 0.3%, to trade at Rs 3,129.85. The total volume of shares traded was 11,903 at the BSE (Friday).